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TObjective: This study was undertaken to characterize morphologic substrate of
tricuspid atresia with ventriculoarterial concordance and discriminate management
strategies that lead to successful definitive repair.
Methods: From 1999 to 2004, a total of 150 babies with type I tricuspid atresia were
enrolled from first diagnosis at 26 institutions. Antegrade pulmonary blood flow was
absent in 19%, restricted in 54%, and unrestricted in 28%. Competing-risk meth-
odology determined the time-related prevalence and risk factors for death versus
cavopulmonary anastomosis and subsequent death versus Fontan completion.
Results: Overall 5-year survival was 86%. Initial palliation included systemic-
pulmonary arterial shunt in 64%, pulmonary artery banding in 11%, and cavopul-
monary anastomosis in 24%. Median age at cavopulmonary anastomosis was 6
months, with 83% undergoing bidirectional Glenn shunt and 17% undergoing
hemi-Fontan procedure. By the age of 2 years, 89% had cavopulmonary anastomo-
sis, 6% were dead, and 4% remained alive without cavopulmonary anastomosis.
Risk factors for death without cavopulmonary anastomosis included presence of
mitral regurgitation (P  .03) and palliation with systemic-pulmonary arterial
shunts not originating from the innominate artery (P .04). Factors associated with
decreased transition rate to cavopulmonary connection included patient variables
(younger admission age to a participating institution, noncardiac anomalies) and
procedural variables (larger systemic-pulmonary arterial shunt diameter, previous
palliation). Of patients undergoing cavopulmonary anastomosis, 75% had under-
gone a Fontan operation within 3 years.
Conclusion: Smaller shunt size and decreased pulmonary blood flow decrease
mortality after initial palliation and increase the rate of successful transition to
cavopulmonary anastomosis. Outcomes can be improved by placing smaller shunts
from the innominate artery, especially in patients with any mitral regurgitation.
Tricuspid atresia with normally related great arteries (type I) is present in 70%of all patients with tricuspid atresia and is the most favorable form ofuniventricular heart necessitating the Fontan-Kreutzer operation.1,2 Patients
with type I tricuspid atresia have an ideal subset of univentricular heart for which to
define outcomes and associated risk factors because they are prevalent, have
favorable outcomes, and are treated with a fairly uniform algorithm. The Congenital
Heart Surgeons’ Society (CHSS) therefore initiated a prospective study in neonates
with type I tricuspid atresia to characterize the relation between morphology and
management strategies leading to definitive repair.
Patients and Methods
Between January 1999 and November 2004, a total of 150 babies younger than 3 months with the
diagnosis of type I tricuspid atresia were prospectively enrolled from 26 participating institutions.
The number of patients enrolled per institution ranged from 1 to 12, with four institutions enrolling
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D9 or more patients. Participation by member institutions was voluntary
and confidential, and ethical approval was obtained per local require-
ments. The CHSS Data Center obtains annual approval from the
Research Ethics Board of the Hospital for Sick Children, Toronto.
Classification
Type I tricuspid atresia is a congenital cardiac malformation with
ventriculoarterial concordance in which the right atrium, in the setting
of ventricular D-loop, fails to open into a ventricle through an atrio-
ventricular valve.3-6 Type I tricuspid atresia is subdivided according
to degree of obstruction to pulmonary blood flow: type Ia has no
antegrade pulmonary blood flow because of pulmonary atresia (n 
28, 19%), type Ib has restricted pulmonary blood flow because of
either pulmonary artery (PA) trunk hypoplasia or restrictive ventric-
ular septal defect (VSD, n  80, 54%), and type Ic has unrestricted
pulmonary blood flow because of a nonrestrictive VSD and absence
of pulmonary stenosis or atresia (n  41, 28%).6
Data Collection
Demographic and morphologic characteristics of all patients are
given in Table E1 and Appendix E1.
Demographic data. Prospective data were collected from sub-
mitted medical records. The study is ongoing, and the most recent
cross-sectional follow-up was performed between September and
November 2004. Follow-up was complete for 132 patients (88%).
Morphologic data. Echocardiographic and catheterization-
derived cardiac structural variables, such as right and left PA dimen-
sions, were converted into Z scores.7,8 A composite mean PA Z score
was then created as follows: (Z score right PA  Z score left PA)/2.
Initial echocardiographic assessment was available for 140 patients
(93%). Initial valvular pathology included mitral regurgitation in 32
cases (34%), aortic regurgitation in 13 (10%), and aortic stenosis in 4
(3%). Follow-up echocardiographic or catheterization assessment was
available in 119 patients (79%) before bidirectional cavopulmonary
anastomosis (BDCPA). Valvular pathology developed in 24 patients,
including mitral regurgitation in 19, aortic regurgitation in 1, and
systemic outflow tract stenosis in 4.
Data Analysis
Because surgical management of tricuspid atresia generally requires a
sequence of procedures (Figure E1), identification of the relationships
between the morphologic substrate and those components of the
management strategy that ultimately lead to a successful Fontan
procedure mandates an analytic approach that considers results of
intermediate, as well as final, stages of repair. Thus in this analysis we
did the following: (1) determined the proportion of patients reaching
defined end states (BDCPA, Fontan completion, death), (2) identified
Abbreviations and Acronyms
BDCPA bidirectional cavopulmonary anastomosis
CHSS  Congenital Heart Surgeons’ Society
LOS  length of stay
PA  pulmonary artery
VSD  ventricular septal defectrisk factors modulating transition into each end state, and (3) created
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tients reaching each defined end state given specific values for these
risk factors.
Multiphase parametric modeling of the hazard function and com-
peting risks methodology were used to determine rates of transition to
mutually exclusive time-related events and to identify incremental
risk factors associated with each transition rate, as previously de-
scribed.9,10 Linearizing transformations including the addition of qua-
dratic terms for continuous predictors, and interactions among re-
tained variables in the model were considered in all cases. Variable
selection was primarily by bootstrap bagging.11
Characteristics of patients at palliation, BDCPA, and Fontan op-
eration are given in Appendix E1 and Tables E2 through E4. In
addition, multivariable linear regression was performed to determine
the relationship between systemic-pulmonary arterial shunt character-
istics, such as diameter and origin, and systemic oxygen saturation
after shunt placement, controlling for other sources of pulmonary
blood flow. This was accomplished by incorporating the status of the
ductus arteriosus and the presence of antegrade flow through the main
PA as binary regressor variables in the model concomitant with the
shunt variables of origin and diameter.
Data are presented as frequency, median with range, or mean
SD as appropriate, with the numbers of missing values indicated.
Percentages, hazard functions, and competing risk estimates are
presented with confidence intervals equivalent to 1 SE (68%). All
data analyses were performed with SAS statistical software (ver-
sion 9; SAS Institute, Inc, Cary, NC).
Results
Overall Mortality
There were 17 deaths: 9 occurred after systemic-pulmonary
arterial shunt operations, 6 after BDCPA, and 2 after Fontan
completion. Overall survival at 5 years was 86% (70%
confidence interval 82%-89%; Figure E2).
Prevalence, Timing, and Factors Predictive of End
States
By 2 years from diagnosis, 6% of patients had died without
BDCPA, 89% had undergone BDCPA, 4% remained alive
without BDCPA or further operation, and 1% had undergone
single-stage Fontan procedures (Figure 1).
Death without BDCPA (n  9). The time-related hazard
function for death without BDCPA was characterized by an
early phase responsible for all nine events. Incremental risk
factors included the presence of mitral regurgitation on initial
echocardiogram (coefficient 1.56  0.70; P  .03) and sys-
temic-PA shunt placement not originating from the innominate
artery (coefficient 1.64  0.79; P  .04; Table 1). Figure 2
shows that patients who had shunts originating from the in-
nominate artery had substantially better survival than did those
with shunts from the subclavian artery or other sites. The
benefit of an innominate artery shunt was magnified in the
presence of mitral regurgitation, as seen in Figure E3).
BDCPA (n  128). The median age at BDCPA was 5.7
months (range 1.7 months–2 years). The time-related hazard
for achievement of BDCPA was characterized by a single early
ember 2005
Karamlou et al Surgery for Congenital Heart Disease
CH
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factors (older age at admission, absence of either smaller or
larger composite PA Z score on admission echocardiogram,
and absence of noncardiac anomalies) and two procedural
variables (smaller absolute systemic-pulmonary arterial shunt
Figure 1. Competing risks depiction of events after diagnosis in
150 patients with tricuspid atresia. All patients began alive and
thereafter migrated to one of four mutually exclusive end states
(death, BDCPA, single-stage Fontan completion, or remaining
alive without BDCPA) at time-dependent rates defined by under-
lying hazard functions. At any point in time, sum of proportions of
children in each state is 100%. For example, estimated preva-
lences after 2 years from diagnosis are as follows: 89% BDCPA;
6% dead without BDCPA, 4% alive without BDCPA, and 1%
single-stage Fontan completion. Solid lines represent parametric
point estimates; dashed lines enclose 70% confidence intervals;
circles with error bars represent nonparametric estimates; num-
bers in parentheses indicate estimated proportions of patients in
each state at 2 years from diagnosis.
TABLE 1. Incremental risk factors for time-related transiti
Variable
For death without BDCPA
Mitral valve regurgitation at initial echocardiogram
Non–innominate artery systemic-pulmonary arterial shunt origi
For survival to BDCPA
Smaller absolute systemic-pulmonary arterial shunt size (per 1
Older age at admission (per 1 y)
Absence of larger or smaller PA Z score at initial echocardiog
No previous palliation
No systemic-pulmonary arterial shunt
Absence of noncardiac anomalies
For survival to Fontan completion
Restrictive VSD on cavopulmonary connection echocardiogram
*Reliability determined by bootstrap bagging (variable resampling) metho
terms, mean combined PA Z score and square of square transformation of me
The Journal of Thoracicdiameter [Figure E4] and absence of palliation before BDCPA)
were associated with a higher likelihood of surviving from
initial diagnosis to BDCPA (Table 1). The risk-adjusted com-
peting risk diagrams shown in Figure 3 illustrate that when a
systemic shunt is required, placing a smaller shunt decreases
mortality and increases the rate of transition to BDCPA.
The second competing risks analysis for events after BD-
CPA predicted that at 3 years from BDCPA, 5% would have
died without a Fontan operation, 75% would have subsequent
Fontan operation, and 20% would remain alive without Fontan
or other operation (Figure 4).
Death after BDCPA without Fontan completion (n 
6). The time-related hazard function for death after BDCPA
without conversion to Fontan circulation was characterized
by a steep early phase accounting for 3 events and an
ongoing late phase accounting for 3 events.
end states after diagnosis (n  150)
Coefficient ( SE) P value Reliability* (%)
1.56 0.70 .03 60%
1.64 0.79 .04 64%
† 7.17 4.74 .13 72%
0.62 0.37 .08 62%
‡ .08 59%
0.66 0.31 .03 62%
0.42 0.28 .10 72%
0.62 0.25 .02 60%
0.81 0.48 .09 62%
fter inverse transformation. ‡Complex polynomial function including two
Figure 2. Mortality without BDCPA stratified by shunt origin.
Patients who had systemic-pulmonary arterial shunts originating
from innominate artery had significantly improved survival rela-
tive to those with shunts from subclavian artery or other sites,





an PA Z score.
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completion was 2.5 years (range 1-5 years). The time-related
hazard function for conversion to Fontan circulation was char-
acterized by a single early phase accounting for all 74 events.
The presence of a restrictive VSD on pre-BDCPA echocardi-
ography was associated with a greater proportion of neonates
reaching Fontan completion (Table 1). The small event num-
Figure 4. Competing-risks depiction of events after BDCPA in 128
patients who underwent BDCPA. Estimated prevalences after 3
years from BDCPA are as follows: 75% Fontan completion, 20%
alive without Fontan conversion, and 5% dead without Fontan
completion. Solid lines represent parametric point estimates;
dashed lines enclose 70% confidence intervals; circles with error
bars represent nonparametric estimates; numbers in parentheses
indicate estimated proportions of patients in each state at 3 years
from BDCPA.
1506 The Journal of Thoracic and Cardiovascular Surgery ● Decber precluded the identification of associated risk factors for
death before Fontan completion.
Management of Competing Sources of Pulmonary
Blood Flow
Main PA trunk ligation occurred in 11 patients at the time of
systemic shunt placement: 8 of these were type Ic and 3 were
type Ib. There were 15 deaths among 121 patients with flow
through the main PA (types Ib and Ic) and 14 deaths among the
68 patients in this group who had a systemic-pulmonary arte-
rial shunt. Eleven of these (16%) occurred in those without
main PA trunk ligation, and 3 (4%) occurred in those with
ligation (P  .21). Thus, there was a trend toward improved
survival among those patients undergoing main PA trunk li-
gation at the time of systemic shunt placement, although it did
not reach statistical significance. It is possible that this benefit
is increased in patients with any degree of mitral valve regur-
gitation, provided the valve is anatomically normal and the
regurgitation is related to ventricular volume loading. New
mitral regurgitation was present in 19 patients at the time of
BDCPA, 14 of whom had preservation of native PA flow and
5 of whom had main PA trunk ligation. There was a trend
toward an increased prevalence of mitral regurgitation among
those without ligation (74% vs 26%, P  .18).
Influence of Age at BDCPA
The ideal age for transition to BDCPA could not be pre-
cisely determined by our analysis, because patient age at
BDCPA was not associated with either death after BDCPA
or survival to Fontan completion. Because the risk factors
identified in our analysis were associated with earlier rates
of transition, however, we explored whether early BDCPA
Figure 3. Smaller systemic-pulmonary arterial shunt
size resulted in decreased mortality and increased
transition rates to BDCPA. A, Use of 3-mm shunt
resulted in 85% of patients having BDCPA by 1 year,
10% still in palliated state, and only 5% of dead. B,
Use of larger 5-mm shunt resulted in much slower
transition rate and slightly increased rate of death
without BDCPA.was correlated with other adverse end points, including
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of stay (LOS) after BDCPA. The median LOS was 6 days
(range 3-351 days). There were 2 in-hospital deaths, 1
occurring 2 weeks after BDCPA and the other occurring
after a prolonged LOS of nearly 1 year. A separate com-
peting risks analysis showed that 60 days after BDCPA,
95% had been discharged alive, 4% were alive but remained
in the hospital, and 1% had died without discharge (Figure
E5). Age at BDCPA was not significantly associated with
either competing outcome, and therefore younger or older




Previous reports have shown that outcomes in infants with
tricuspid atresia and normally related great arteries are consid-
erably better than for other morphologic substrates of single-
ventricle physiology.12-14 We have shown that mortality oc-
curs primarily at the initial palliation stage before BDCPA and
that outcomes beyond transition to BDCPA are excellent.
The presence of mitral regurgitation at initial echocardiog-
raphy (34%) and systemic-pulmonary arterial shunts not orig-
inating from the innominate artery were associated with death
without conversion to BDCPA. The association between sys-
temic atrioventricular valve regurgitation and adverse outcome
in patients with single-ventricle physiology is well known.15-17
The deleterious effects of significant mitral regurgitation may
be potentiated by pulmonary overcirculation related to the
Figure 5. Proportion of patients discharged alive after BDCPA
stratified by patient age at BDCPA. Of 128 patients undergoing
BDCPA, 126 were discharged alive. Multivariable competing
risks equation for survival to hospital discharge was solved for
hypothetic patient weighing 3.7 kg with previous palliation at
three different values for age at BDCPA. Age at BDCPA did not
influence either hospital LOS or in-hospital mortality. Youngest
patients in our study undergoing BDCPA (at about 2 months) fared
no worse than did those of median or older age.maintenance of additional sources of competing pulmonary
The Journal of Thoracicblood flow. Ventricular unloading has been shown to be re-
duced in this setting.18 Patients in our study who had under-
gone palliation and had antegrade pulmonary blood flow
tended to have an increased prevalence of mitral regurgitation
(74%) before BDCPA relative to those who underwent main
PA trunk ligation (26%). Although we cannot provide conclu-
sive evidence that PA trunk ligation is the optimal strategy in
all cases, our data show that reduced pulmonary blood flow
may lead to improved outcomes, especially in patients with
any degree of mitral regurgitation.
The influence of shunt origin on mortality risk is complex,
because the shunt may be only one determinant of total pul-
monary blood flow. However, innominate artery shunts had a
smaller indexed size (1.15 mm/kg) than did those originating
from alternate sites, reflecting preferential use of 3.5-mm
shunts (as opposed to 4.0-mm shunts) in this population.
Smaller shunt size is consistent with previous data from a
canine model of univentricular heart that showed systemic-
pulmonary arterial shunts with indexed size 0.8 to 1.0 to result
in more favorable outcomes.19 In agreement with these find-
ings, our multivariable analysis demonstrated that patients with
innominate artery shunts had lower postoperative oxygen sat-
uration after controlling for other sources of pulmonary blood
flow, indicating a reduction in the shunt contribution to total
pulmonary blood flow. Appropriate shunt sizing therefore may
mitigate the tendency toward excessive shunt flow, because the
predominant determinant of flow becomes the diameter of the
smaller shunt, rather than the diameter of the larger originating
vessel. This finding was confirmed recently in a computational
fluid dynamic model in which innominate artery diameter and
insertion angle had negligible influence on pressure-flow
relationships.20
A previous report from Sittiwangkul and colleagues13 has
suggested that central shunt origin in patients with tricuspid
atresia may predispose toward pulmonary overcirculation and
contribute to PA distortion. The disadvantage imparted by
non–innominate artery origin, however, may be a surrogate for
other morphologic or technical covariates, in that the selection
of alternate shunt origination site in our series often reflected
the presence of other unfavorable anatomic characteristics that
precluded the use of the innominate artery.
Transition to BDCPA
The favorable influence of older presenting age on outcomes in
patients with tricuspid atresia has been previously de-
scribed12,13,21 and may be related to natural selection. Patients
in our study who were admitted at an older age generally had
balanced physiology and therefore underwent BDCPA without
previous palliation.
Our data showing that smaller systemic-pulmonary arterial
shunt diameter favors transition to BDCPA is concordant with
a previous CHSS report on patients with hypoplastic left heart
syndrome in which lower post-Norwood oxygen saturation
and Cardiovascular Surgery ● Volume 130, Number 6 1507
Surgery for Congenital Heart Disease Karamlou et al
CH
Dand smaller indexed shunt size were also associated with
increased rates of transition.14 Thus smaller shunt size and less
total pulmonary blood flow not only decrease mortality after
initial palliation but also increase the rate of successful transi-
tion to BDCPA.
The optimal timing for BDCPA has not been conclusively
determined, in part because general consensus dictates that
transition occur between 3 months and 1 year, so there are few
patients undergoing BDCPA at extremes of age. In addition,
the scarcity of adverse events (death or not reaching Fontan
completion) among patients with type I tricuspid atresia ham-
pers risk-factor identification. In our study, the median age at
BDCPA was 6 months, and the procedure was almost univer-
sally performed after the age of 2 months (with 2 exceptions,
at 1.7 and 1.8 months) and rarely after 1 year. Patient age at
BDCPA was not a predictor of end state achievement, nor was
it associated with increased hospital LOS. However, an impor-
tant corollary is that no significant disadvantage was imparted
by earlier BDCPA transition. Valid arguments exist in support
of earlier conversion, including optimization of pulmonary/
systemic blood flow ratio, decreased single-ventricle volume
load, and preservation of PA architecture.22 The long-term
myocardial benefits of early volume load reduction have im-
portant implications, because myocardial failure is among the
most important causes of morbidity and mortality among pa-
tients with univentricular heart independent of Fontan comple-
tion.23 Two clinical studies have shown acceptable outcomes
in patients undergoing BDCPA between 2 and 6 months but
significantly increased mortality and BDCPA takedown rate
when the procedure was attempted before the age of 2
months.22,24 The benefits of limited pulmonary blood flow and
early conversion must therefore be weighed against the risk of
premature BDCPA performance, which according to our and
others’ data may potentially be defined as 2 months of age.24
Study Limitations
Although this study represents the largest prospective cohort of
patients with tricuspid atresia, and a comprehensive set of
variables was used, lack of statistical power and missing data
points are potential weaknesses. The current data set did not
include sufficient interstage longitudinal measures of PA and
ventricular size, nor were there sufficient quantitative valvular
or ventricular function indices. Incorporation of this data could
have allowed determination of the influence of different man-
agement strategies, particularly related to accessory pulmonary
blood flow, on growth of anatomic structures and single-
ventricle performance.
Conclusions
We have shown that demographic, morphologic, and proce-
dural characteristics have important influences on the propor-
tion of patients reaching each end state and that outcomes
beyond conversion to BDCPA are excellent. Results in babies
1508 The Journal of Thoracic and Cardiovascular Surgery ● Decwith tricuspid atresia may be improved by placing systemic
shunts from the innominate artery, using the smallest systemic
shunt possible to achieve adequate oxygen saturation, and
interrupting competing sources of pulmonary blood flow in
patients with any degree of mitral regurgitation. Delaying
BDCPA beyond 2 months of age confers no discernible benefit
with regard to hospital LOS, mortality, or achievement of
Fontan completion.
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cardiology colleagues for their contributions to this study. We ac-
knowledge the assistance of personnel from the CHSS Data Center,
particularly Geraldine Cullen-Dean, Sally Cai, Olga Levesque, and
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of these data.
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Discussion
Dr Hillel Laks (Los Angeles, Calif). Dr Karamlou, that was a
beautifully presented article. I also want to give my thanks and
credit to the Congenital Heart Surgeons’ Society, to Dr Williams,
who runs the data center, and to the rest of the group that reviewed
and presented these data.
At UCLA at and many other centers, the ideal management of
tricuspid atresia, or single-ventricle heart, would include the follow-
ing: control of pulmonary blood flow at an early age, preferably
younger than 1 month, which would include reducing flow if it is
excessive or providing a shunt if it is not; a cavopulmonary connec-
tion at approximately 3 months regardless of whether there are ade-
quate oxygen saturations and an adequate shunt or blood flow; and a
Fontan operation preferably at 4 to 5 years of age.
All the deaths before cavopulmonary connection occurred after the
systemic-pulmonary arterial shunt. The data also shows that mitral
regurgitation was associated with most of the mortality, and larger
polytetrafluoroethylene shunt size was associated with a delayed
cavopulmonary shunt.
Dr Karamlou, was there a cohort who received early control of
pulmonary blood flow and a cavopulmonary connection electively
at 3 months of age who might be compared with a group who did
not, to look at the question as to whether a rigidly controlled
method of treatment at each stage would result in a better out-
come?
Dr Karamlou. Regarding your question about performing a
controlled study, this was a prospective observational study, and
The Journal of Thoracicwe therefore made no attempt to mandate management at any of
the participating institutions.
Regarding the management of pulmonary blood flow, most pa-
tients without pulmonary atresia who received systemic-pulmonary
arterial shunts actually had maintenance of antegrade flow through the
native PA. Cavopulmonary connection was almost universally per-
formed between 2 months and 1 year of age. The variable of age at
cavopulmonary connection was analyzed as a continuous variable,
and we therefore did not dichotomize or categorize it, nor did we use
a particular age to define whether 3 versus 4 months was the ideal age
for performing cavopulmonary connection.
I can say, however, that the youngest patient in our study who
underwent cavopulmonary connection was aged 1.7 months. There
have been other articles which suggest that earlier cavopulmonary
connection may be beneficial as long as it’s not performed before 2
months of age, and I think our data tend to agree with this point.
Dr Laks. Another interesting finding was the apparent impor-
tance of the point of origin for a shunt, with better results with the
innominate artery origin than with the subclavian artery, aorta, or
carotid artery. There was also a correlation with delayed cavopul-
monary shunt and shunt size, suggesting that patients were fol-
lowed up as long as their oxygen saturations were adequate.
Were the larger shunts used in the procedures that were not from
the innominate artery in origin, subclavian and aortic, mostly the large
polytetrafluoroethylene grafts that were used, relative to the innomi-
nate group, and would this explain the difference? Because there was
a time when for subclavian shunts it was suggested that the proximal
subclavian would control flow and it was therefore okay to use a
5-mm polytetrafluoroethylene graft, which we in our own experience
have found not to be acceptable and to result in overcirculation. So
was this specific to institutional choice of shunt size rather than point
of origin? And was it related to polytetrafluoroethylene shunt size
rather than point of origin?
Dr Karamlou. As you have alluded to, trying to dissect out the
effect of shunt size from the overall contribution of pulmonary blood
flow is complex, because the shunt is only one determinant of total
pulmonary blood flow. Most of the shunts that were placed from the
innominate artery were actually downsized to 3.5 mm, compared with
a 4-mm or larger shunt that was generally placed from an alternative
site, either the subclavian artery or centrally from the aorta.
There have been data from a canine model of univentricular
heart to suggest that an optimal indexed shunt size to body weight
close to 1 mm/kg provides the best matching between pulmonary
and systemic blood flows. The innominate artery shunts were
closer to this value at 1.1 than were the larger indexed shunt size
used for either the subclavian or the aortic point of origin. So I do
think that perhaps the innominate artery origin may be a surrogate
for smaller shunt size, but it also may be a surrogate for more
favorable morphologic type. For instance, in some cases, an aber-
rant right subclavian artery or exceedingly small head vessels
precluded the use of the innominate artery. This could explain the
favorable influence of the site of origin.
Dr Laks. I think it would be worth clarifying this, because the
conclusion drawn that these other sites of origin are intrinsically
not good might not be warranted by the data because of institu-
tional bias.
At UCLA, most cavopulmonary connections are done off pump;
only a small minority are done on pump, and only if other procedures
and Cardiovascular Surgery ● Volume 130, Number 6 1509
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Dare done or if the total pulmonary blood flow would be occluded by
the application of clamps with cannulation of the superior vena cava
and the right atrial appendage. In this study, 70% of connections were
done with bypass, and 17% were done with circulatory arrest. It
would be interesting to compare the morbidity, including neurologic
effects and blood use, and the cost between these two groups. Cer-
tainly, medicolegal issues, even if not substantiated, could be raised
with the use of circulatory arrest for a procedure that could be done
without it.
Do you have data regarding any difference in morbidity and
mortality between the on-pump and off-pump groups?
Dr Karamlou. We didn’t specifically look at on-pump versus
off-pump procedures, because the numbers of cases performed off
pump was actually very small. The patients who had circulatory arrest
were those who underwent a hemi-Fontan operation as opposed to a
bidirectional Glenn shunt.
I do agree that looking at neurologic morbidity as well as cost
might be useful in the future. As I noted in the beginning, this is an
ongoing study, and enrollment continues. So perhaps in the next
couple of years, if everybody keeps enrolling their patients, we may
have sufficient data to answer this question.
Dr Laks. My final comment and question regard the contro-
versy as to whether at the time of cavopulmonary connection an
additional source of pulmonary blood flow should be left. At
UCLA, we have made it our practice as often as possible to leave
an additional source of pulmonary blood flow, and that would be
a tightened band or a shunt made slightly smaller. The advantage,
theoretically, is that you would have a total pulmonary/systemic
blood flow ratio aimed at 1.0 to 1.3. And because the superior vena
cava only provides a pulmonary to systemic blood flow ratio of
0.35, you would have a normal amount of pulmonary blood flow,
and not an excessive amount or too small an amount, and could
delay the Fontan completion until about 4 or 5 years of age, when
an adult-sized conduit could be used. In addition, during that time,
the child would have a chance to respond to exercise, because
systemic hypertension during exercise would increase pulmonary
blood flow.
In this particular study, were you able to look at those who did
have an additional source of flow and those who did not, and whether
this influenced outcome and what influence it had on the time of
Fontan completion?
Dr Karamlou. The issue of competing sources of pulmonary
blood flow was a question we initially had tremendous interest in
exploring, for the reasons that you mentioned. There is significant
controversy in the literature regarding this issue. Certain authors
have advocated that leaving an additional source of pulmonary
blood flow reduces arteriovenous malformation formation and, as
you say, may also postpone the need for Fontan operation to a later
age. However, Mainwaring and colleagues have indicated that
leaving additional sources of pulmonary blood flow in their series
1510 The Journal of Thoracic and Cardiovascular Surgery ● Decof 92 patients actually increased morbidity and had an unfavorable
impact on outcomes.
In our study, patients who had an additional source of pulmonary
blood flow, usually antegrade flow through the native PA, had an
increased incidence of mitral regurgitation, which portended poorer
outcomes in our current series. Two other papers, one from my own
institution, showed that delaying the age at Fontan operation actually
led to worse outcomes after Fontan operation. Although the study
reported here did not focus on post-Fontan outcomes, this is some-
thing that we will certainly explore at as the cohort matures.
Dr Charles D. Fraser, Jr (Houston, Tex). Congratulations on
an excellent analysis, but I wonder if you might explore another
inference. If I understand your data correctly, the patients who died
with shunts in place were older, meaning a longer transition time from
the newborn period to the cavopulmonary anastomosis. Our friends
from Wisconsin have taught us that in a more complicated single-
ventricle model, the hypoplast, a close surveillance program decreases
interstage mortality. Isn’t this just another example of interstage
mortality, and shouldn’t one of the inferences be that we need to
follow all our single-ventricle patients much more closely and perhaps
refer them for cavopulmonary anastomosis earlier?
Dr Karamlou. That is a good point. It also raises another
interesting point: although tricuspid atresia with normally related
great arteries has favorable morphologic type compared with other
forms of univentricular heart, there is still significant interstage
mortality. I agree that a surveillance program for all single-ven-
tricle patients would probably lead to improved outcomes.
Dr Christo I. Tchervenkov (Montreal, Quebec, Canada).
Congratulations, I enjoyed your presentation. I wonder if you can
give us your thoughts on the fact that, unlike in this article or this
cohort of patients with tricuspid atresia, where age at Glenn shunt
was perhaps associated with better outcome, in a similar cohort of
patients with hypoplastic left heart syndrome after the Norwood
operation, the opposite was found. That, is younger age at Glenn
shunt was associated with a higher mortality. How do you contrast
these two different findings? Can you explain them? Could per-
haps a comparison study be undertaken to try to tease out why in
this series young age at Glenn was better and in the either series
was not as good?
Dr Karamlou. I cannot speculate as to exactly what the differ-
ences are because there was no comparison made. I believe an
important distinction between the two groups is that in the Norwood
series, all of the patients were completely shunt dependent, and
shunt-related thrombosis or other shunt-related problems would there-
fore be disastrous. This may be one reason that optimal timing of
cavopulmonary connection may differ between the cohorts. Also, the
right ventricular morphology in the Norwood group, as opposed to the
left ventricular morphology in the tricuspid atresia cohort, may also
alter the optimal window for cavopulmonary connection.
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DAppendix E1
Procedural Characteristics at Palliation
Details regarding procedural characteristics at palliation with a
systemic-pulmonary arterial shunt or PA band are shown in Table
E2. Balloon septostomy was performed in 23 patients. Palliation
was performed in 149 patients: systemic-pulmonary arterial shunt
in 96 (64%), initial BDCPA in 36 (24%), and PA trunk banding in
17 (11%). One infant enrolled in 2004 was alive without any
operation.
Systemic-Pulmonary Arterial Shunt Characteristics
Patients undergoing systemic-pulmonary arterial shunt placement
were younger (median age 7 days) than those undergoing PA trunk
banding (median age 47 days, P  .004) but had equivalent body
weight. The operative approach for systemic shunt placement was
through median sternotomy in 69 patients and thoracotomy in 27
patients. Subclavian artery origin was universally used in those
undergoing thoracotomy. The carotid artery was used in 2 patients,
both of whom had aberrant right subclavian artery, and central
shunts originating from the aorta were used in those with hypo-
plastic PAs or small arch vessels that precluded their use. Of the 96
patients who underwent systemic-pulmonary arterial shunt place-
ment, concomitant interruption of competing sources of pulmonary
blood flow included ligation of the main PA trunk in 11 and
ligation of a patent ductus arteriosus in 33. Shunts originating from
the innominate artery were the most common (65%) and when
indexed to body weight were smaller than shunts originating from
other locations (1.15  0.24 mm/kg vs 1.31  0.56 mm/kg, P 
.07). At discharge, unadjusted postoperative oxygen saturation was
83% in those with innominate artery shunts versus 85% for those
with shunts originating from other locations among the 85 patients
(89%) for whom data were available. By multivariable analysis,
after controlling for shunt diameter and other sources of pulmo-
nary blood flow, this difference was 2.9  1.4 (P  .04), indicat-The Journal of Thoracic anmonary blood flow. Eight patients required subsequent systemic-
pulmonary arterial shunt revision or replacement for shunt
thrombosis (n  4), failed BDCPA (n  2), or other technical
considerations (n  2).
PA Banding Characteristics
PA trunk banding (n  17) occurred exclusively in patients with
unrestricted pulmonary blood flow. Previous PA trunk banding
was not associated with the development of a restrictive VSD or
systemic outflow tract obstruction at the pre-BDCPA evaluation.
Procedural Characteristics at Cavopulmonary
Connection
Details regarding procedural characteristics at BDCPA are listed in
Table E3. The median age at BDCPA was 6 months (range 2.3
months–1.9 years). BDCPA followed systemic-pulmonary arterial
shunt placement in 76 patients, followed PA trunk banding in 16,
and was the initial procedure in 36 patients. BDCPA was used in
83%, with a hemi-Fontan procedure performed in 17%. Pulmonary
arterioplasty (right PA greater than left PA) was the most frequent
concomitant procedure and was slightly more prevalent among
those with previous systemic shunt placement (17% vs 9%, P not
significant).
Procedural Characteristics at Fontan Completion
Details regarding the procedural characteristics at Fontan comple-
tion are listed in Table E4. Fontan completion occurred as a
single-stage operation in 2 patients after systemic-pulmonary ar-
terial shunt placement and in 74 patients after BDCPA. The
median age at Fontan completion was 2.5 years (range 1.1-4.9
years), and the median interval from BDCPA was 1.9 years
(range 6 months–3.6 years). The extracardiac Fontan procedure
was used in 53% and the lateral tunnel was used in 35%.ing that non–innominate artery shunts resulted in higher total pul- Fenestration was used in 63%.d Cardiovascular Surgery ● Volume 130, Number 6 1510.e1
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DFigure E1. Flow chart depicting events from diagnosis among 150 patients with tricuspid atresia. One patient
enrolled during 2004 remains alive without operation. All other patients underwent palliation consisting of
systemic-pulmonary arterial shunt, PA banding, or initial BDCPA. Nine deaths occurred after systemic-PA shunt
placement, and 128 patients had BDCPA. Of those who had BDCPA, 7 died: 6 before Fontan completion and 2 after
Fontan conversion. Seventy-four patients underwent staged Fontan completion. Two patients had single-stage
Fontan completion after systemic-pulmonary arterial shunt placement.1510.e2 The Journal of Thoracic and Cardiovascular Surgery ● December 2005
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DTABLE E1. Initial patient characteristics (n  150)
Variable Value Deaths (n  17) No. missing
Demographic characteristics
Birth weight (kg, median and range) 3.2 (1.0-4.7) 28
Age at diagnosis (d, median and range) 0 (0-62) 0
Admission age (y, median and range) 0 (0-1.7) 5
Sex (female/male) 73:77 7:10 0
Noncardiac anomaly (No.) 27 (18%) 6 (11%) 0
Morphologic characteristics
Type of tricuspid atresia (No.)
Type Ia 28 (19%) 2 (1%) 1
Type Ib 80 (54%) 10 (7%) 1
Type Ic 41 (28%) 5 (3%) 1
Right aortic arch (No.) 2 (2%) 0 (0%) 34
Patent ductus arteriosus (No.) 93 (71%) 11 (8%) 19
Restrictive atrial septal defect (No.) 11 (9%) 0 (0%) 27
Left superior vena cava (No.) 14 (13%) 1 (1%) 38
Aortic valve stenosis (No.) 4 (3%) 2 (1%) 15
Aortic valve regurgitation (No.) 13 (10%) 3 (2%) 15
Mitral valve regurgitation (No.) 32 (24%) 7 (5%) 16
Branch PA stenosis (No.) 2 (1%) 0 (0%) 34
Aberrant right subclavian artery (No.) 2 (1%) 1 (1%) 0
Anomalous pulmonary venous drainage (No.) 1 (1%) 1 (1%) 27
VSD size (mm, mean  SD) 5.5 2.5 91
Left PA Z score (median and range) !1 (!6 to 4) 56
Right PA Z score (median and range) !1 (!6 to 4) 55
Combined mean Z score* (median and range) !1 (!5 to 3) 56
Pulmonary valve annulus (mm, mean  SD) 6.5  2.2 95
*Combined mean Z score  (right PA Z score  left PA Z score)/2.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 6 1510.e3
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DTABLE E2. Procedural characteristics at palliation (n  149)
Variable Value No. missing
Type of palliation (No.)
Systemic-pulmonary arterial shunt 96 (64%) 0
PA band 17 (11%) 0
Cavopulmonary connection 36 (24%) 0
Systemic-pulmonary arterial shunt characteristics (n  96)
Age (d, median and range) 7 (0-138) 0
Weight (kg, mean  SD) 3.4 1.0 9
Location of shunt origin (No.)
Innominate artery 62 (65%) 0
Subclavian artery 28 (29%) 0
Other site 6 (6%) 0
Operative approach (No.) 0
Median sternotomy 69 (72%) 0
Thoracotomy 27 (28%) 0
Indexed shunt size (mm/kg, mean  SD) 1.2 0.3 15
Main PA ligation (No.) 11 (11%) 0
Patent ductus arteriosus ligation (No.) 33 (35%) 3
Preoperative saturation (%, mean  SD) 74 18 13
Postoperative saturation (%, mean  SD) 85 11 11
Cardiopulmonary bypass used (No.) 16 (17%) 0
Circulatory arrest (No.) 4 (4%) 0
PA band characteristics (n  17)
Age (d, median and range) 47 (0-14) 0
Weight (kg, mean  SD) 3.8 0.9 3
TABLE E3. Procedural characteristics at BDCPA (n  128)
Variable Value No. missing
Initial BDCPA (No.) 36 (28%) 0
Age (median and range) 5.7 m (1.7 m-1.9 y) 0
Weight (kg, mean SD) 6.5 1.3 12
Type of BDCPA (No.)
Bidirectional Glenn shunt 106 (83%) 0
Hemi-Fontan procedure 22 (17%) 0
CPB time (min, mean SD) 68 40 23
Circulatory arrest used (No.) 21 (17%) 3
Postoperative saturation (%, mean SD) 84% 6% 21
Myocardial protection method (No.)
Cardioplegia used 45 (40%) 16
No aortic crossclamp 58 (52%) 16
Fibrillation, no cardioplegia used 9 (8%) 16
Concomitant procedures (No.)
Right pulmonary arterioplasty 32 (26%) 3
Left pulmonary arterioplasty 19 (15%) 8
Main PA band 8 (6%) 0
Main PA ligation 59 (48%) 0
1510.e4 The Journal of Thoracic and Cardiovascular Surgery ● December 2005
Karamlou et al Surgery for Congenital Heart Disease
CH
DTABLE E4. Characteristics at Fontan completion (n  76)
Variable Value No. missing
Single-stage Fontan (No.) 2 (3%) 0
Age (y, median and range) 2.4 (0.9-4.9) 0
Weight (kg, mean  SD) 12.9  3.1 9
Type of Fontan procedure (No.)
Extracardiac conduit 40 (53%) 1
Lateral tunnel 35 (47%) 1
Conduit material (No.)
Polytetrafluoroethylene 66 (90%) 3
Allograft 3 (4%) 3
Pericardium 4 (5%) 3
Fenestration performed (No.) 47 (63%) 1
Fenestration size (mm, median and range) 4 (2-7) 33
Postoperative saturation (%, mean  SD) 93% 6% 38
Cardiopulmonary bypass time (min, mean  SD) 81 31 25
Circulatory arrest used (No.) 7 (9%) 0
Main PA ligation (No.) 14 (18%) 74
Figure E2. Overall time-related survival among 150 patients with tricuspid atresia. Solid lines represent parametric
point estimates enclosed by 70% confidence intervals; circles with error bars represent nonparametric estimates;
numbers in parentheses represent number of patients traced at that point.
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DFigure E3. A, Predicted mortality without achievement of BDCPA stratified by systemic-pulmonary arterial shunt
origin in absence of mitral valve regurgitation (MR). B, Predicted mortality without achievement of BDCPA
stratified by systemic-pulmonary arterial shunt origin in presence of mitral valve regurgitation. Although non–
innominate artery shunt origin results in decreased survival in both conditions, its unfavorable influence is greater
in presence of significant mitral regurgitation. Solid lines represent continuous parametric estimates.
Figure E4. Predicted achievement of and transition rates to BDCPA from diagnosis stratified by type of palliation
and size of initial systemic-pulmonary arterial shunt. Five lines represent five specific solutions to multivariable
equation for achievement of BDCPA for hypothetic patient without additional anomalies admitted at 1 year of age.
Mean values were used for other continuous predictors. For patients requiring systemic-pulmonary arterial shunt,
placement of smaller diameter shunt is associated with greatest prevalence of patients reaching defined end state.
Solid lines represent continuous parametric point estimates.
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DFigure E5. Competing risks diagram of events after BDCPA to hospital discharge. Median LOS was 6 days (range
3-351 days). Competing risks analysis showed that 60 days after BDCPA, 95% were discharged alive, 4% remained
alive in hospital, and 1% died without discharge.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 6 1510.e7
